Phase 3 Duchenne Muscular Dystrophy Clinical Trials
5 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–5 of 5 trials
Recruiting
Phase 3
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
Duchenne Muscular Dystrophy
Solid Biosciences Inc.80 enrolled5 locationsNCT07160634
Recruiting
Phase 3
Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
Muscular Dystrophy, DuchenneDMDNeuromuscular Diseases (NMD)+10 more
Dyne Therapeutics90 enrolled1 locationNCT07608432
Recruiting
Phase 2Phase 3
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
Duchenne Muscular Dystrophy
Italfarmaco206 enrolled39 locationsNCT03373968
Recruiting
Phase 2Phase 3
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
REGENXBIO Inc.65 enrolled17 locationsNCT05693142
Recruiting
Phase 3
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Italfarmaco138 enrolled20 locationsNCT05933057